恶性间皮瘤：从发病到治疗
Malignant mesothelioma: development to therapy.
作者信息
Thompson Joyce K, Westbom Catherine M, Shukla Arti
机构信息
Pathology Department, University of Vermont, College of Medicine, Burlington, Vermont.
出版信息
J Cell Biochem. 2014 Jan;115(1):1-7. doi: 10.1002/jcb.24642.
Abstract
Malignant mesothelioma (MM) is an aggressive cancer of the mesothelium caused by asbestos. Asbestos use has been reduced but not completely stopped. In addition, natural or man-made disasters will continue to dislodge asbestos from old buildings into the atmosphere and as long as respirable asbestos is available, MM will continue to be a threat. Due to the long latency period of MM development, it would still take decades to eradicate this disease if asbestos was completely removed from our lives today. Therefore, there is a need for researchers and clinicians to work together to understand this deadly disease and find a solution for early diagnosis and treatment. This article focuses on developmental mechanisms as well as current therapies available for MM.
摘要
恶性间皮瘤（MM）是一种由石棉引起的侵袭性间皮癌。石棉的使用已有所减少，但尚未完全停止。此外，自然或人为灾害将继续使石棉从旧建筑物中释放到大气中，只要有可吸入的石棉存在，MM就将继续构成威胁。由于MM发展的潜伏期很长，即使今天石棉已从我们的生活中完全消除，根除这种疾病仍需数十年时间。因此，研究人员和临床医生需要共同努力，了解这种致命疾病，并找到早期诊断和治疗的解决方案。本文重点关注MM的发病机制以及现有的治疗方法。
相似文献
1
Malignant mesothelioma: development to therapy.恶性间皮瘤：从发病到治疗
J Cell Biochem. 2014 Jan;115(1):1-7. doi: 10.1002/jcb.24642.
2
Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.环氧化酶-2、表皮生长因子受体和芳香化酶信号在炎症和间皮瘤中的作用。
Mol Cancer Ther. 2013 Jun;12(6):844-52. doi: 10.1158/1535-7163.MCT-12-1103. Epub 2013 May 31.
3
Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.石棉相关肺癌和胸膜恶性间皮瘤：当前若干问题
Semin Respir Crit Care Med. 2015 Jun;36(3):334-46. doi: 10.1055/s-0035-1549449. Epub 2015 May 29.
4
Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma.有霍奇金和非霍奇金淋巴瘤放疗史患者的恶性间皮瘤的临床病理特征。
J Clin Oncol. 2013 Dec 20;31(36):4544-9. doi: 10.1200/JCO.2013.49.9616. Epub 2013 Nov 18.
5
[Malignant pleural mesothelioma].[恶性胸膜间皮瘤]
Ugeskr Laeger. 2018 Apr 9;180(15).
6
Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China.中国东部石棉暴露与恶性间皮瘤发病率的关联
JAMA Oncol. 2017 Apr 1;3(4):562-564. doi: 10.1001/jamaoncol.2016.5487.
7
Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).长纤维碳纳米管复制了石棉诱导的间皮瘤，同时破坏了肿瘤抑制基因 Cdkn2a（Ink4a/Arf）。
Curr Biol. 2017 Nov 6;27(21):3302-3314.e6. doi: 10.1016/j.cub.2017.09.007.
8
The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province, Turkey.土耳其锡瓦斯省恶性间皮瘤病例与环境石棉暴露的评估。
Environ Geochem Health. 2014 Feb;36(1):55-64. doi: 10.1007/s10653-013-9518-y. Epub 2013 Apr 4.
9
Diagnostic biomarker of asbestos-related mesothelioma: example of translational research.石棉相关间皮瘤的诊断生物标志物：转化研究实例
Cancer Sci. 2007 Aug;98(8):1147-51. doi: 10.1111/j.1349-7006.2007.00520.x. Epub 2007 May 25.
10
Peritoneal mesothelioma: the site of origin matters.腹膜间皮瘤：起源部位至关重要。
Am Soc Clin Oncol Educ Book. 2013:182-8. doi: 10.14694/EdBook_AM.2013.33.182.
引用本文的文献
1
Pyroptosis: shedding light on the mechanisms and links with cancers.细胞焦亡：揭示机制与癌症的关联。
Front Immunol. 2023 Nov 2;14:1290885. doi: 10.3389/fimmu.2023.1290885. eCollection 2023.
2
Identification of Highly Sensitive Pleural Effusion Protein Biomarkers for Malignant Pleural Mesothelioma by Affinity-Based Quantitative Proteomics.基于亲和的定量蛋白质组学鉴定恶性胸膜间皮瘤高度敏感的胸腔积液蛋白质生物标志物
Cancers (Basel). 2023 Jan 19;15(3):641. doi: 10.3390/cancers15030641.
3
Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.细胞外信号调节激酶5与间皮瘤进展中的炎性小体
Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.
4
Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.优化载有吉西他滨的明胶纳米载体的研制及其在肺癌中的应用。
J Aerosol Med Pulm Drug Deliv. 2017 Oct;30(5):299-321. doi: 10.1089/jamp.2015.1286. Epub 2017 Mar 9.
5
Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials.纵向数据与生存数据联合建模中的贝叶斯模型评估及其在癌症临床试验中的应用
J Comput Graph Stat. 2017;26(1):121-133. doi: 10.1080/10618600.2015.1117472. Epub 2017 Feb 16.
6
Asbestos-Induced Mesothelial to Fibroblastic Transition Is Modulated by the Inflammasome.石棉诱导的间皮细胞向成纤维细胞转变受炎性小体调控。
Am J Pathol. 2017 Mar;187(3):665-678. doi: 10.1016/j.ajpath.2016.11.008. Epub 2017 Jan 3.
7
Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis.去铁胺排铁在石棉诱导的间皮细胞癌变中的双重预防作用
Cancer Sci. 2016 Jul;107(7):908-15. doi: 10.1111/cas.12947. Epub 2016 Jun 13.
8
Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.人胸膜和腹膜间皮细胞对石棉暴露的易感性差异
J Cell Biochem. 2015 Aug;116(8):1540-52. doi: 10.1002/jcb.25095.
9
Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials.评估纵向数据与生存数据联合模型中的模型拟合及其在癌症临床试验中的应用。
Stat Med. 2014 Nov 30;33(27):4715-33. doi: 10.1002/sim.6269. Epub 2014 Jul 20.
本文引用的文献
1
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).硼替佐米联合顺铂一线治疗恶性胸膜间皮瘤的 II 期研究及前瞻性验证无进展生存率作为间皮瘤临床试验的主要终点（欧洲癌症研究与治疗组织 08052）。
Eur J Cancer. 2013 Sep;49(13):2815-22. doi: 10.1016/j.ejca.2013.05.008. Epub 2013 Jun 20.
2
EphB4 as a therapeutic target in mesothelioma.EphB4 作为间皮瘤的治疗靶点。
BMC Cancer. 2013 May 30;13:269. doi: 10.1186/1471-2407-13-269.
3
A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.一种使用抗 podoplanin 抗体的恶性间皮瘤新型靶向治疗方法。
J Immunol. 2013 Jun 15;190(12):6239-49. doi: 10.4049/jimmunol.1300448. Epub 2013 May 20.
4
Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections.根治性胸膜切除术和放化疗治疗恶性胸膜间皮瘤：不完全切除的结果。
Lung Cancer. 2013 Aug;81(2):241-6. doi: 10.1016/j.lungcan.2013.04.019. Epub 2013 May 17.
5
Accurate diagnosis of mesothelioma: more important than ever.间皮瘤的准确诊断：比以往任何时候都更重要。
Arch Pathol Lab Med. 2013 May;137(5):601-2. doi: 10.5858/arpa.2012-0260-ED.
6
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.三氧化二砷与厄洛替尼协同抗癌作用的机制是抑制 EGFR 介导的 DNA 双链断裂修复。
Mol Cancer Ther. 2013 Jun;12(6):1073-84. doi: 10.1158/1535-7163.MCT-13-0065. Epub 2013 Apr 2.
7
RNA blood levels of osteopontin splice variants are cancer markers.骨桥蛋白剪接变体的RNA血液水平是癌症标志物。
Springerplus. 2013 Dec;2(1):110. doi: 10.1186/2193-1801-2-110. Epub 2013 Mar 14.
8
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.间皮素在胸腔积液中的诊断价值：与 CYFRA 21-1 和 CEA 的比较。
Med Oncol. 2013 Jun;30(2):543. doi: 10.1007/s12032-013-0543-6. Epub 2013 Mar 27.
9
Extracellular signal-regulated kinase 5: a potential therapeutic target for malignant mesotheliomas.细胞外信号调节激酶 5：恶性间皮瘤的潜在治疗靶点。
Clin Cancer Res. 2013 Apr 15;19(8):2071-83. doi: 10.1158/1078-0432.CCR-12-3202. Epub 2013 Feb 27.
10
Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.曾暴露于石棉的电力行业工人中，间皮素和骨桥蛋白水平随时间的变化。
Int Arch Occup Environ Health. 2014 Feb;87(2):195-204. doi: 10.1007/s00420-013-0853-1. Epub 2013 Feb 20.
Zotero 插件